Ibraheem (Ibs) Mahmood, DrugDev president and CEO, has been named one of the PharmaVOICE 100 most inspiring people in the life sciences industry. DrugDev is a provider of technology-driven solutions that help investigators, sponsors and CROs do more trials together.
The PharmaVOICE 100 is an annual compilation of individuals recognized for their positive contributions to the global industry. The panel of expert judges selected Ibs Mahmood for his vision and successful strategy to push far more medicines through the development process by guiding pharma to leverage technology to improve the cost and effectiveness of clinical trials.
Since joining DrugDev in 2011, Mahmood has grown the company from a handful of people to a world-class team—including recent acquisitions of CFS Clinical and TrialNetworks—backed by Invesco Perpetual.
Mahmood said, “'Disruptive innovation' is a catchphrase that is gaining popularity in pharma, and for good reason. As an industry, we have hundreds, if not thousands, of promising drug candidates which have been deemed too expensive to test. What if we come together and change the game by making life easier for sites and by connecting them with sponsors and CROs?
“I believe we will be able to do more trials, evaluate these drugs properly, and bring products to market that will improve the lives of potentially millions of patients worldwide,” said Mahmood. “This is our mission at DrugDev and we are thrilled to see the industry agree that the time has come to make it happen through real disruption.”
Previous PharmaVOICE 100 honoree Dr. Hugo Stephenson, executive chairman of DrugDev and creator of the DrugDev Innovation Lab, said, “When it comes to clinical research, change is inspiring, and we are delighted to see Ibs receive this well-deserved recognition. With DrugDev, Ibs is not satisfied with leading a company that simply provides better solutions—our shared goal is to completely transform the way clinical research is conducted on a global basis.”